Investor Relations
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 2, 2021Proprietary platform includes countertop device being developed for Co-Diagnostics by world experts in rapid PCR
-
Feb 25, 2021Clinical Reference Laboratory's FDA-authorized saliva-based PCR test uses technology developed by Co-Diagnostics to detect SARS-CoV-2
-
Feb 23, 2021Company also elevates in-house Senior VP of Biochemistry to Chief Scientific Officer
-
Feb 16, 2021Company believes direct saliva to play a key role in high throughput, point of care, and at home applications
-
Jan 28, 2021The Company's Logix Smart™ SARS-CoV-2 DS (Direct Saliva) test is designed to reduce sample processing time and cost by eliminating the extraction process
-
Dec 22, 2020Proprietary Company design process facilitates rapid response in detecting mutation of a new coronavirus strain circulating in the UK
-
Dec 14, 2020Company anticipates Q4 revenue will significantly exceed previous quarter
-
Nov 17, 2020New tests expand global reach of Company COVID-19 test menu
-
Nov 16, 2020Company also announces receipt of CE markings for both Logix Smart ABC and SARS-CoV-2 2-gene tests
-
Sep 24, 2020Company expects to begin taking orders from US CLIA labs first week of October 2020
-
Sep 1, 2020
-
Aug 13, 2020Company reports robust sales of COVID-19 tests and net income per common share of $0.43
-
May 26, 2020Tissue from presymptomatic patient in Italy was found to contain SARS-CoV-2 using Company’s Logix Smart™ COVID-19 test kit
-
May 14, 2020Company reports robust sales of COVID-19 tests as Co-Diagnostics generates net profit through middle of second quarter
-
Mar 20, 2020Company accelerates U.S. sales of COVID-19 test pursuant to new FDA policy
-
Feb 24, 2020Logix Smart™ COVID-19 Test now available for export from the United States as a CE-marked IVD